REVIEW Structural Insights Into AGC Kinase Inhibition
Source: Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics, Volume 14, Number 6, 2003 , pp. 267-278(12)
Publisher: Cognizant Communication Corporation
Abstract:The AGC group of protein kinases comprises several targets for small molecule inhibitors of therapeutic significance. Crystal structure data facilitate the design or improvement of selective inhibitory molecules. Cross-selectivity of kinase inhibitors is often observed among closely related enzymes. Usually an obstacle for inhibitor design, cross-selectivity can be useful to obtain structural data from a related kinase, if not available from the original target. Protein kinase A (PKA), a representative of the AGC kinase group, has been cocrystallized with AGC group inhibitors from diverse chemical groups, thus providing structural information about binding modes, selectivity, and cross-selectivity. “Ersatz” kinases were created by mutating the inhibitor binding site of PKA to resemble other related kinases from the AGC group. The cocrystallization of these ersatz kinases with certain AGC group small molecule inhibitors elucidated some aspects of protein kinase inhibitor selectivity in this group of kinases.
Document Type: Review Article
Affiliations: 1: *Abteilung Strukturforschung, Max-Planck-Institut fuer Biochemie, D-82152 Martinsried, Germany 2: †Department for Pathochemistry, German Cancer Research Centre, Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany
Publication date: 2003
- Formerly: Oncology Research Incorporating Anti-Cancer Drug Design
Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.